Recycling minocycline

Paratek Pharmaceuticals Inc. and Serono S.A. don't fully understand why the antibiotic minocycline and its non-antibacterial derivatives have activity against multiple sclerosis in animals. But the in vivo data are sufficiently robust to warrant moving ahead, and Serono says its interest in finding novel oral therapies for MS made

Read the full 493 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE